Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of HRS9531 in adults with obesity and obstructive sleep apnea
CTR20243163Phase 2Active
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Sep 2024
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of HRS9531 in obesity, obstructive sleep apnea hypopnea syndrome (OSAHS), sponsored by Fujian Shengdi Pharmaceuticals. Started Sep 2024; status: active.
02
Drugs
HRS9531
03
Conditions
obesityobstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on CTR20243163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243163.